New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
06:06 EDTCYTRCytRx's aldoxorubicin for sarcomashows positive Phase 2b clinical trial results
CytRx's oral presentation titled “Randomized phase 2b trial comparing first-line treatment with aldoxorubicin versus doxorubicin in patients with advanced soft tissue sarcomas,” was featured in The Lancet Oncology in its July issue. The updated results from CytRx’s ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable STS demonstrated that aldoxorubicin significantly increases progression-free survival, PFS at 6 months, overall response rate and tumor shrinkage, compared to doxorubicin, the current standard-of-care, as a first-line treatment in patients with STS. The data trended in favor of aldoxorubicin for all of the major subtypes of STS. The company is on track to report the full overall survival results from this trial prior to year-end.
News For CYTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
06:10 EDTCYTRCytRx initiates global Phase 2 clinical trial of aldoxorubicin
CytRx announced the initiation of a global Phase 2b clinical trial evaluating aldoxorubicin compared to topotecan in subjects with extensive-stage small cell lung cancer, or SCLC, who have relapsed or were refractory to prior chemotherapy. Aldoxorubicin is CytRx's modified version of the widely-used chemotherapeutic agent, doxorubicin. CytRx has received Orphan Drug Designation for the treatment of SCLC from the FDA. Enrollment is expected to be completed in 2015 and PFS data are anticipated by mid-2016. The study is expected to involve approximately 40 clinical trial sites in the U.S., Spain, Italy and Hungary.
September 29, 2014
06:18 EDTCYTRCytRx receives multiple FDA orphan drug designations for aldoxorubicin
Subscribe for More Information
September 26, 2014
11:04 EDTCYTRCytRx drug granted orphan designation in treatment of various cancers
Subscribe for More Information
10:03 EDTCYTRCytRx treatment of glioblastoma multiforme granted FDA orphan status
The FDA designated aldoxorubicin from CytRx for orphan drug status as a treatment of glioblastoma multiforme, according to a post to the agency's site. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use